Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 1083 (114th)

Medicare Drug Savings Act of 2015

referredUnited States· United States Congress· EN

Introduced

23 April 2015

Last action

23 April 2015 · Introduced

Status

Read twice and referred to the Committee on Finance.

Sponsors

Sen. Nelson, Bill [D-FL], Sen. Whitehouse, Sheldon [D-RI], Sen. Blumenthal, Richard [D-CT], Sen. Franken, Al [D-MN], Sen. Hirono, Mazie K. [D-HI], Sen. Baldwin, Tammy [D-WI], Sen. Reed, Jack [D-RI], Sen. Klobuchar, Amy [D-MN], Sen. Shaheen, Jeanne [D-NH], Sen. Leahy, Patrick J. [D-VT], Sen. Boxer, Barbara [D-CA], Sen. Brown, Sherrod [D-OH], Sen. Udall, Tom [D-NM], Sen. Sanders, Bernard [I-VT], Sen. Durbin, Richard J. [D-IL], Sen. Merkley, Jeff [D-OR], Sen. King, Angus S., Jr. [I-ME], Sen. Stabenow, Debbie [D-MI]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Medicare Drug Savings Act of 2015 Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act (SSAct) to require drug manufacturers to pay the Secretary of Health and Human Services drug rebates for rebate eligible (low-income) individuals. Excludes from Medicare coverage as a part D drug any drug or biological manufactured by a manufacturer that has not entered into and have in effect a rebate agreement with the Secretary. Requires a rebate agreement to require a drug or biological manufacturer to provide to the Secretary a rebate, determined according to a specified formula, for each rebate period ending after December 31, 2015, for any covered Medicare part D drug dispensed after that date to any rebate eligible individual for which payment was made by a prescription drug plan sponsor or MedicareAdvantage organization for such period. Specifies a formula for determination of Medicaid rebate amounts for such drugs or biologicals. Amends SSAct title XIX (Medicaid) to exclude any amounts paid under a rebate agreement from the determination of best price and average manufacturer price under the Medicaid program.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 23 April 2015

    Introduced

    Read twice and referred to the Committee on Finance.

    Source: IntroReferral

  2. 23 April 2015

    Introduced

    Introduced in Senate

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in Senate (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (text)

    Introduced in Senate · EN · 23 April 2015

    ViewDownloadOpen at official source

  • Introduced in Senate (PDF)

    Introduced in Senate · EN · 23 April 2015

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate

    summary · EN · 23 April 2015

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.